Oslo Cancer Cluster

D.B.R.K. Gupta Udatha

Overview

Profile:
64% completed

About us

Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and treatment. We mostly do this trough wide dissemination of knowledge and innovations.

We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field. They represent the entire oncology value chain, doing everything from exploratory research to selling therapeutics and diagnostics to global markets.

Norwegian Centre of Expertise In 2007, we became a Norwegian Centre of Expertise. Since then, we have developed into a strong biotech cluster well positioned in the global oncology industry. The world class research environment in immunotherapy and the presence of several IT-companies, strengthen the cluster’s position as a global knowledge and innovation centre in the cancer field.

Our Incubator Environment Around 30 of the members are gathered in the Oslo Cancer Cluster Incubator, a successful biotech cluster, situated in the Oslo Cancer Cluster Innovation Park. We share the innovation park with Ullern Upper Secondary Schoolthe Cancer Registry of Norway and Oslo University Hospital.

Next door is the leading comprehensive cancer hospital in Northern Europe, Oslo University Hospital Radiumhospitalet, and its Institute for Cancer Research. We collaborate closely with them, and we have a long-term school-industry collaboration with Ullern Upper Secondary.

Immuno-Oncology A growing number of members in the cluster develop novel cancer immunotherapies. Therefore, we established the Norwegian Immuno-Oncology Consortium in 2013. The goal of the consortium is to strengthen the knowledge-base and expertise, and to facilitate more national and international collaboration within immuno-oncology. The consortium also addresses precision medicine.

Precision Medicine Healthcare is becoming digitized. New technology, including tumour sequencing, is generating vast amounts of data that needs to be sorted and analysed. This has opened for IT-companies to take part in developing personalized medicine, tailoring drugs to the biology of each patient.

We use global connections and national advantages to help get the right treatment to the right patient at the right time. New technology helps us. Software companies, like IBM Watson and SAS Institute, are part of our cluster. We are part of EU projects such as  PERMIDES, and of collaborations with technological research facilities such as the Lawrence Livermore National Laboratory in the US and the Cancer Registry of Norway.

Oslo Cancer Cluster initiated National Cancer Genomic Consortium in 2012. It consists of clinicians and specialised cancer research groups collaborating on two large research projects that aim to establish new clinical practises for cancer treatment.

Formalised strategy
Strategy focus on internationalisation

Cluster composition

  • 100
    Cluster Members
  • 40
    SME's
  • 40
    Large Companies
  • 10
    Research Organisations, Universities, Technology Centers
  • 0
    Other Ecosystem Actors

Management team

D.B.R.K. Gupta Udatha
ECCP Responsible Person
D.B.R.K. Gupta Udatha
Project Manager
Ketil Widerberg
Cluster Manager
Jutta Heix
Internationalisation Responsible

Sectorial and industrial focus

Sectoral Industries
Technology fields
S3 EU priority areas
Cross-sectoral industries
Biopharmaceuticals

Services

Support services provided

Other (please specify)

Further information

Oslo Cancer Cluster is a non profit member- and network organization for industry, organizations, research institutions, finance institutions and development actors in the field of cancer R&D. 

Oslo Cancer Cluster wants to include more members from all parts of Norway and abroad. As a member you will  contribute to the vision of Oslo Cancer Cluster: To improve the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.

MEMBER BENEFITS

This list states the services provided to members of Oslo Cancer Cluster SA (‘the Cluster’). This information is provided as part of the membership agreement.

International Network:

The Cluster facilitates participation in national and international conferences.

The Cluster’s secretariat prepares themes and programmes for professional meetings and other forums on the basis of input received from cluster members.

The Cluster’s secretariat offers advice and help in establishing direct connections between cluster members and relevant national and international partners.

Wide dissemination of members R&D activities and results:

Member profiles on the Cluster website, with direct links to the members’ own websites.

Logo promotion in national and international forums where the Cluster is represented.

Active showcasing and exposure of participating members at national and international conferences and professional meetings

Active use of the Cluster’s website and social media to distribute research results and other news from members to general public.

Media consulting and pitching news items from cluster members to the media.

Access to the Cluster’s media contacts.

Contribute during each stage of the innovation process: 

If desired manage intellectual property rights to be owned by the member, including filing and prosecution activities relating to patents for an agreed compensation

If desired negotiate and enter into agreements on member’s behalf with development and commercial partners for an agreed compensation

Engage and coordinate professional advisors

Contribute with available capabilities, experiences and large global network to help convert research results and new knowledge into innovations

A politically neutral channel for information about framework conditions of importance to all the members

Meetings with public authorities in order to influence the health authorities to improve the framework conditions for biotechnology, cancer research and the health system in general

Courses and competence-raising measures 

Advice and assistance in the preparation of marketing material, presentation and investor pitches

Advice on business development, marketing plans and strategy plans

Advice and assistance in the preparation of articles, articles and letters to the editor

Please also see the Oslo Cancer Cluster Membership Agreement.

Cooperation activities

International cooperation

Targeted countries

United States

Transnational cooperation

Targeted countries

Austria
Denmark
Finland
Germany
Sweden

Transnational support activites

Support to collaborative activities/etc.

International support activites

Support to collaborative activities/etc.

Upcoming events

Monday Tuesday Wednesday Thursday Friday Saturday Sunday
29
30
31
1
2
3
4
 
 
 
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
 
 

Latest news and documents

News Achievements Published: 17.06.2018
A successful end of the successful project: PERMIDES
News Published: 04.03.2018
Join the R&D Network Meeting on “Blockchain & Distributed Ledger Innovations for eHealth”
News Document Published: 11.02.2018
Welcome to R&D Network Meeting in Oslo: Blockchain & Distributed Ledger Innovations for eHealth